Загрузка...
Efficacy and safety of concurrent chemoradiotherapy with or without Nimotuzumab in unresectable locally advanced squamous cell carcinoma of head and neck: Prospective comparative study - ESCORT-N study
BACKGROUND: Nimotuzumab is an anti-epidermal growth factor receptor monoclonal antibody which can be added to chemoradiotherapy (CRT) to improve efficacy for management of locally advanced squamous cell carcinoma of the head and neck (LASCCHN). We prospectively evaluated the efficacy and safety of n...
Сохранить в:
| Опубликовано в: : | South Asian J Cancer |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Wolters Kluwer - Medknow
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6498712/ https://ncbi.nlm.nih.gov/pubmed/31069191 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/sajc.sajc_38_18 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|